Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Lotan, Yair; Woldu, Solomon; Sanli, MEHMET; Black, Peter; Milowsky, Matthew

doi:10.1111/bju.14220

Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Lotan Y., Woldu S. L., Sanli O., Black P., Milowsky M. I.

BJU international, cilt.122, sa.3, ss.434-440, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 122 Sayı: 3
Basım Tarihi: 2018
Doi Numarası: 10.1111/bju.14220
Dergi Adı: BJU international
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.434-440
Anahtar Kelimeler: biomarker, cost, neoadjuvant chemotherapy, response, #BLCSM, #BladderCancer, RADICAL CYSTECTOMY, PATHOLOGICAL STAGE, OUTCOMES, CARE, TRENDS
İstanbul Üniversitesi Adresli: Hayır

Özet

ObjectivesTo model the cost-effectiveness of a biomarker-based approach to select patients for neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC).